19th EURETINA Congress Keynote Lecture: Diabetic Retinopathy Today

被引:22
作者
Bandello, Francesco [1 ,2 ]
Cicinelli, Maria Vittoria [1 ,2 ]
机构
[1] Univ Vita Salute San Raffaele, Sch Med, Milan, Italy
[2] IRCCS San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy
关键词
Optical coherence tomography; Panretinal photocoagulation; Diabetic retinopathy; Diabetic macular edema; Anti-vascular endothelial growth factor; ARGON-GREEN LASER; PANRETINAL PHOTOCOAGULATION; MACULAR EDEMA; FLUORESCEIN ANGIOGRAPHY; PITUITARY ABLATION; EYES; OPHTHALMOSCOPE; RANIBIZUMAB; DIODE; BLOOD;
D O I
10.1159/000506312
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
In the last decades, significant changes have been taking place regarding the pathogenesis of diabetic retinopathy (DR) and the complex mechanisms that eventually lead to the various manifestations of the disease, including diabetic macular edema (DME). DR was first considered a pure microvascular disease, due to the evident capillary structural changes (microaneurysms), fluid extravasation, and lipid exudation. With the advent of fundus fluorescein angiography, the concept of ischemia and the correlation between peripheral nonperfusion and neovascularization has been introduced, which was eventually followed by the advent of new therapeutic strategies, such as peripheral photocoagulation. Nowadays, thanks to more advanced imaging techniques, namely optical coherence tomography (OCT), OCT angiography, and wide-field imaging (imaging up to 200 degrees of the retina in a single shot), it became clear that other elements participate in the occurrence of DR and DME, including inflammation and neurodegeneration. In the future, integration of standard investigations with new diagnostic devices would allow the prompt recognition of DR even before clinical signs of the disease are ophthalmoscopically evident, and the development of personalized treatment for both retinopathy and DME will be available.
引用
收藏
页码:163 / 171
页数:9
相关论文
共 83 条
[1]  
[Anonymous], 1978, Ophthalmology, V85, P82
[2]  
[Anonymous], 1981, Invest Ophthalmol Vis Sci, V21, P1
[3]  
[Anonymous], 1991, Ophthalmology, V98, P786
[4]  
[Anonymous], 1985, Ophthalmology, V92, P492
[5]   Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up [J].
Arevalo, J. Fernando ;
Sanchez, Juan G. ;
Fromow-Guerra, Jans ;
Wu, Lihteh ;
Berrocal, Maria H. ;
Farah, Michel E. ;
Cardillo, Jose ;
Rodriguez, Francisco J. .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2009, 247 (06) :735-743
[6]  
ATMACA LS, 1995, ACTA OPHTHALMOL SCAN, V73, P303
[7]  
Ballantyne A J, 1944, Br J Ophthalmol, V28, P593, DOI 10.1136/bjo.28.12.593
[8]   RELATION BETWEEN IRIDOPATHY AND RETINOPATHY IN DIABETES [J].
BANDELLO, F ;
BRANCATO, R ;
LATTANZIO, R ;
GALDINI, M ;
FALCOMATA, B .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1994, 78 (07) :542-545
[9]   DIODE VERSUS ARGON-GREEN LASER PANRETINAL PHOTOCOAGULATION IN PROLIFERATIVE DIABETIC-RETINOPATHY - A RANDOMIZED STUDY IN 44 EYES WITH A LONG FOLLOW-UP TIME [J].
BANDELLO, F ;
BRANCATO, R ;
TRABUCCHI, G ;
LATTANZIO, R ;
MALEGORI, A .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 1993, 231 (09) :491-494
[10]  
Bandello F, 2003, Semin Ophthalmol, V18, P251